Corporate News Blog – RXi Pharma Collaborates with Gustave Roussy, Europe’s Leading Cancer Centre

Research Desk Line-up: Jazz Pharma Post Earnings Coverage

LONDON, UK / ACCESSWIRE / November 15, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for RXi Pharmaceuticals Corp. (NASDAQ: RXII) (“RXi”), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=RXII. The Company announced on November 13, 2017, that it has signed a collaborative research agreement with Gustave Roussy to evaluate the potential of RXi’s novel sd-rxRNA technology platform for use in cancer treatments. Gustave Roussy is a leading Comprehensive Cancer Centre in Europe. For immediate access to our complimentary reports, including today’s coverage, register for free now at:

http://protraderdaily.com/register/

Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) for due-diligence and potential coverage as the Company announced on November 07, 2017, its financial results for Q3 2017 and updated financial guidance for 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Jazz Pharma when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on RXII; also brushing on JAZZ. Go directly to your stock of interest and access today’s free coverage at:

http://protraderdaily.com/optin/?symbol=RXII

http://protraderdaily.com/optin/?symbol=JAZZ

Scope of the agreement

As per the terms of the collaborative research agreement between RXi and Gustave Roussy, the research will include the design and evaluation of sd-rxRNA compounds in a human tumor xenograft model. If the results are positive, these compounds can be further developed and used in treatment of cancer. The financial and other terms of the agreement were not shared by the Company.

Commenting on the collaborative agreement with Gustave Roussy, Dr. Geert Cauwenbergh, President and CEO of RXi Pharma, said:

“We are excited to be working with Gustave Roussy on this research effort. We believe that our sd-rxRNA technology platform is broadly applicable to many therapeutic areas, including cancer. Considering our sd-rxRNA development for immuno-oncology applications, we look forward to working with the exceptional team at this prominent cancer center to leverage their expertise in this area.”

Professor Caroline Robert, MD, PhD, Head of the Dermatology Unit at Gustave Roussy Institute, which focuses on skin cancer research, added:

“the innovative technology developed by RXi will allow us to address several critical questions in the field of cancer research and to explore future potential use of siRNAs in the clinic.”

About RXi’s sd-rxRNA

RNAi is a naturally occurring phenomenon by which short double-stranded RNAs interfere with the expression of targeted genes. The development of therapeutics based on RNAi technology takes advantage of this phenomenon and potentially allows us to reduce the expression of particular genes within living cells. Scientists at RXi have used an alternative approach to delivery in which drug-like properties were built into the RNAi compound itself. These novel compounds are termed ‘self-delivering’ RNAi compounds (sd-rxRNA). The proprietary combination of chemical modifications that results in spontaneous cellular uptake of sd-rxRNA without the need for a delivery vehicle was discovered through systematic medicinal chemistry screening. sd-rxRNAs are hybrid oligonucleotide compounds that RXi believes combine the beneficial properties of both conventional RNAi and antisense technologies.

Treatment of multiple cell types with sd-rxRNA resulted in the efficient and universal cellular uptake. Efficient cellular uptake was observed both in vitro and in vivo, including tissues like skin, retina, lung, spinal cord, and liver. The Company’s research data suggests that efficient uptake of sd-rxRNA compounds might be achieved in any tissue as long as the route of administration enables local delivery of a relatively high concentration of the compound. RXi believes that sd-rxRNA technology has the potential to be developed into pipeline of clinical programs to treat a wide range of diseases, where local administration is an option.

The current collaboration is part of RXi’s efforts to expand this technology to systemic applications.

About Gustave Roussy

Villejuif Cedex, France based Gustave Roussy is the premier European Cancer Centre which offers patient care, research, and teaching. Patients with all types of cancer can be treated at the institute. It employs an integrated approach to research, patient care, and teaching in order to benefit patients, and it brings together all the skills which are essential for top quality research in oncology. This encompasses basic research, clinical research, and translational research to link the two. The institute has nearly 3,000 employees of which 545 are doctors, 1200 are nursing staff, and 300 are researchers

About RXi Pharmaceuticals Corp.

RXi Pharma is a clinical-stage Company developing innovative therapeutics, based on its proprietary RNAi technology platform, for significant unmet needs. The Company’s current focus areas using this technology include dermatology, ophthalmology, and cell-based immunotherapy. RXi’s extensive patent portfolio provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas. The Company actively pursues research collaborations, partnering, and out-licensing opportunities with academia and pharmaceutical companies.

Last Close Stock Review

On Tuesday, November 14, 2017, the stock closed the trading session at $0.57. A total volume of 211.76 thousand shares have exchanged hands. RXi Pharma’s stock price surged 13.70% in the last one month, 0.98% in the past three months, and 1.54% in the previous six months. The stock currently has a market cap of $12.51 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 482042